Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic (Nasdaq: HOLX) launches the #BustTheMyth campaign for Breast Cancer Awareness Month, aiming to debunk common misconceptions about breast cancer, mammograms, and breast density. The company will ring the Nasdaq opening bell for the 18th year to kick off this initiative.
The campaign addresses key myths, such as the misconception that only those with a family history need mammograms, when in fact 85% of women diagnosed have no family history. It also emphasizes that breast density, a risk factor for breast cancer, can only be determined by mammograms.
Hologic's effort comes at a important time, following updated breast cancer screening guidelines and new FDA reporting standards on breast density. The company's 3D Mammography™ exam is FDA-approved as superior for women with dense breasts compared to 2D alone.
Despite breast cancer being highly treatable when detected early, over 40% of U.S. women report skipping screenings. Hologic aims to empower women with facts to prioritize their health and encourage annual screenings.
Hologic (Nasdaq: HOLX), a leading medical technology company focused on women's health, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 5th at 12:20 p.m. Eastern Time in New York.
The company will engage in a fire-side chat presentation, which will be webcast live and accessible through the investors section of Hologic's website. The webcast will remain available for 30 days following the event, providing an opportunity for investors and interested parties to gain insights into Hologic's latest developments and strategies.
This presentation at a major healthcare conference underscores Hologic's commitment to transparency and engagement with the investment community, potentially impacting investor perceptions and the company's stock performance.
Hologic (NASDAQ: HOLX) reported strong financial results for Q3 fiscal 2024, with revenue of $1,011.4 million, up 2.7% year-over-year. GAAP EPS was $0.82, and non-GAAP EPS was $1.06, both exceeding guidance. Organic revenue excluding COVID-19 grew 5.8% in constant currency. Key highlights include:
- Diagnostics revenue increased 0.3%, with Molecular Diagnostics up 2.8%
- Breast Health revenue rose 6.9%, driven by strong gantry sales and service
- Surgical revenue grew 5.9%
- Cash flow from operations was $405.7 million
- The company repurchased 1.4 million shares for $100 million
Hologic raised its full-year 2024 revenue guidance to $4,012 - $4,027 million and non-GAAP EPS guidance to $4.04 - $4.11. The company's strong performance demonstrates the durability of its broad portfolio across Diagnostics, Breast Health, and Surgical franchises.
Hologic (Nasdaq: HOLX) has completed its acquisition of Endomagnetics (Endomag), a UK-based developer of breast cancer surgery technologies, for approximately $310 million. This acquisition adds Endomag's wireless breast surgery localization and lymphatic tracing solutions to Hologic's breast surgery portfolio, including the Magseed® marker, Magtrace® lymphatic tracer, and Sentimag® platform.
The integration aims to provide breast surgeons and radiologists with an expanded range of options and enhanced user experience. Hologic's President of Breast and Skeletal Health Solutions, Erik Anderson, expressed enthusiasm about increasing access to Endomag's innovative technologies and improving outcomes for patients. Endomag's CEO, Eric Mayes, shared optimism about the opportunities for their team and the potential to impact more women globally.
A recent survey by Hologic reveals a significant gap in health screenings among American women. Despite 90% of women acknowledging the importance of regular screenings, 72 million have skipped or delayed essential tests, such as those for breast, cervical, and colorectal cancers. The Hologic Global Women's Health Index, conducted by Gallup, surveyed 4,001 women and found key barriers including lack of awareness, anxiety, and time constraints. The study highlights the need for increased awareness and education to encourage timely screenings.
Hologic (Nasdaq: HOLX) announced that it will release its financial results for the third quarter of fiscal 2024 on July 29, 2024, after the market closes.
Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. To participate, dial (888) 394-8218 in the U.S. and Canada, or +1 (773) 305-6853 internationally, using access code 5372869. Alternatively, participants can join the webcast on Hologic's investor relations website.
A live and recorded webcast replay will be available on the website for 30 days, starting about two hours after the call concludes.
Hologic focuses on medical technologies that improve women's health and well-being through early detection and treatment.
Hologic (Nasdaq: HOLX) has announced its participation in two upcoming investor conferences. The company will present at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on May 29th at 10 a.m. CT. Additionally, Hologic will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois on June 4th at 8:40 a.m. CT. Both presentations will be webcast live and available for 30 days on the company’s investor relations website.
Hologic, Inc. (Nasdaq: HOLX) announced Q2 fiscal 2024 results, with revenue of $1,017.8M, GAAP EPS $0.72, Non-GAAP EPS $1.03, exceeding guidance. Total company organic revenue growth was 4.9% in constant currency. The company raised full-year revenue midpoint and EPS guidance.
Hologic, Inc. (Nasdaq: HOLX) announced the acquisition of Endomagnetics for $310 million, enhancing their breast surgery portfolio with innovative technologies. The deal is expected to expand options for breast cancer procedures, increase global access to advanced solutions, and improve patient care. Endomag's revenue in 2023 was approximately $35 million. The acquisition will be slightly dilutive to Hologic's non-GAAP earnings per share in 2024, break even in 2025, and accretive thereafter.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
